Non-small cell lung cancer (NSCLC) remains a significant clinical challenge, particularly for patients who do not respond to standard immune checkpoint blockade (ICB). The Zhang Lab at OSU recently uncovered a genetic vulnerability that could change how we select patients for PD-L1 therapy

The team investigated the role of PPP2R2A which is underexpressed in over 40% of NSCLC cases. They found that when this protein is insufficient, the result is a cascade of "good" immune events:

• Replication Stress (RS): PPP2R2A loss induces RS and DNA double-strand breaks.
• Cytosolic DNA: This stress causes DNA to leak into the cytoplasm, forming micronuclei.
• cGAS-STING: The leaked DNA triggers the cGAS-STING-type I IFN pathway, essentially "priming" the tumor for an immune attack.

What makes this study particularly exciting for immunotherapy researchers is how the TME changed. The lab observed:

Increased NK Cell Infiltration: Boosting innate antitumor responses.

Reduced Treg Function: PPP2R2A-deficient tumors showed fewer and less functional immunosuppressive Tregs.

Enhanced CD8+ T Cell Activity: Upon PD-L1 blockade, these "primed" tumors showed a massive influx of cytotoxic T cells.

The Zhang Lab utilized several ichorbio in vivo antibodies to validate these findings in syngeneic models:

• Anti-mouse PD-L1 (Clone 10F.9G2): Used to demonstrate the sensitization of PPP2R2A-deficient tumors.
• Isotype Controls (Rat IgG2b): Critical for baseline validation in their mouse models.